Literature DB >> 14693111

Antimuscarinics for treatment of overactive bladder.

Karl-Erik Andersson1.   

Abstract

For many years, antimuscarinic drugs have been the first-line pharmacological treatment for urgency, frequency, and urge incontinence, all symptoms of the disorder termed overactive bladder. Antimuscarinic treatment is not always effective and is associated with side-effects that limit its clinical use. The clinical significance of the effects of antimuscarinic drugs has been questioned lately. In this review, the rationale for the use of these drugs in the management of overactive bladder is re-examined and the results of treatment are discussed. I conclude that these drugs are the only treatment with undisputed effectiveness in the treatment of overactive bladder. They may not be the perfect treatment for all patients with this disorder, but their value for individual patients should not be underestimated. Further clinical trials with improvement in quality of life as the primary endpoint are needed and may give a fair reflection of the clinical value of antimuscarinic drugs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14693111     DOI: 10.1016/s1474-4422(03)00622-7

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  103 in total

1.  Economic evaluation of sacral neuromodulation in overactive bladder: A Canadian perspective.

Authors:  Magdy M Hassouna; Hamid Sadri
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

2.  Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB.

Authors:  Linda Brubaker; Angelo Gousse; Peter Sand; Catherine Thompson; Vaishali Patel; Jihao Zhou; Brenda Jenkins; Karl-Dietrich Sievert
Journal:  Int Urogynecol J       Date:  2012-01-25       Impact factor: 2.894

3.  Time-to-effect with darifenacin in overactive bladder: a pooled analysis.

Authors:  Vik Khullar; Jenelle Foote; Yodit Seifu; Mathias Egermark
Journal:  Int Urogynecol J       Date:  2011-10-18       Impact factor: 2.894

Review 4.  Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.

Authors:  Paul Abrams; Karl-Erik Andersson; Jerry J Buccafusco; Christopher Chapple; William Chet de Groat; Alison D Fryer; Gary Kay; Alan Laties; Neil M Nathanson; Pankaj Jay Pasricha; Alan J Wein
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

Review 5.  [Epidemiology and pathophysiology of overactive bladder].

Authors:  S Schumacher
Journal:  Urologe A       Date:  2006-07       Impact factor: 0.639

Review 6.  [Anticholinergics for overactive bladder: does subtype selectivity play a role?].

Authors:  M C Michel; M M Barendrecht; M Oelke
Journal:  Urologe A       Date:  2006-07       Impact factor: 0.639

7.  Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study.

Authors:  Seung Hwan Lee; Seok Soo Byun; Seung Ju Lee; Khae Hawn Kim; Ji Youl Lee
Journal:  Int Urol Nephrol       Date:  2013-10-05       Impact factor: 2.370

8.  Evaluation and management of the non-motor features of Parkinson's disease.

Authors:  Steven Wishart; Graeme J A Macphee
Journal:  Ther Adv Chronic Dis       Date:  2011-03       Impact factor: 5.091

Review 9.  [Anticholinergic treatment of overactive bladder syndrome. Is it all the same?].

Authors:  T Schneider; M C Michel
Journal:  Urologe A       Date:  2009-03       Impact factor: 0.639

Review 10.  Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations.

Authors:  Hashim Hashim; Paul Abrams
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.